智通财经APP讯，联邦制药(03933)发布公告，于2025年7月4日，公司全资附属公司联邦生物科技(珠海横琴)有限公司(联邦生物科技)研发的1类创新药UBT37034注射液关于超重或肥胖适应症的新药临床试验注册申请(IND)获美国食品药品监督管理局(FDA)批准，IND编号为175188。
UBT37034注射液是由联邦生物科技开发的具有独立自主知识产权的1类创新药。UBT37034是一款新型多肽类受体激动剂，可通过选择性作用于神经肽Y2受体减轻体重。临床前多种动物模型研究结果显示，UBT37034与GLP-1类似物联用能够显著降低体重。
未来，公司将持续致力于新产品研发，并重点提升在生物医药行业的竞争力及创造力，预期将为公司及其股东创造更大收益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.